



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board
Thursday, March 14, 2019, 2:00pm
DMAS 7B Conference Room
Agenda

1. **Call to Order and Introductions** – Kathleen Sardegna, MD, Chair
2. **Minutes** - Approval of Minutes from December 13, 2018 meeting
3. **RetroDUR Criteria Estimates**
4. **New Drugs - Grid**
 - a. Copiktra™ (duvelisib)
 - b. Daurismo™ (glasdegib)
 - c. Libtayo® (cemiplimab-rwlc)
 - d. Lorbrena® (lorlatinib)
 - e. Panzyga® (human normal immunoglobulin, IVIg)
 - f. Talzenna™ (talazoparib)
 - g. Vitrakvi® (larotrectinib)
 - h. Vizimpro® (dacomitinib)
 - i. Xospata® (gilteritinib)
 - j. Xyosted™ (testosterone enanthate)
 - k. Drug Updates: New Generics; New Dosage Form/ Strength/ Biosimilar; PDL-Eligible; Physician Administered Drugs; Antihemophilic Drug Factors.
5. **Physician-Administered Drugs**
 - a. Crysvita® (burosumab-twza)
 - b. Ilumya™ (tildrakizumab-asmn)
6. **Specialty Drugs**
7. **Topics for Discussion**
 - a. Analysis of Compounded Medications



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

- b. Pediatric and Adult Opioid Utilization
- c. Concurrent Use of Opioids and Benzodiazepines
- d. Opioid Use with Risk Factors and No Naloxone
- e. Antipsychotic Duplication
- f. DUR Quarterly Newsletter

8. Reports

- a. ProDUR
- b. RetroDUR
- c. Utilization Analysis

9. Adjournment

DRAFT